Oak Ridge Investments LLC Increases Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Key Points

• Oak Ridge Investments LLC increased its stake in Intuitive Surgical by 6.9%, owning 18,197 shares valued at approximately $9 million, making it the 28th largest position in their portfolio.
• Insiders at Intuitive Surgical sold a total of 15,859 shares worth about $7.9 million over the last 90 days, indicating a decrease in their ownership percentages.
• Analysts have mixed opinions on Intuitive Surgical, with the stock having a consensus rating of "Moderate Buy" and an average price target of $595.95, while some firms have lowered their ratings.

Oak Ridge Investments LLC boosted its position in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 6.9% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 18,197 shares of the medical equipment provider's stock after acquiring an additional 1,176 shares during the period. Intuitive Surgical accounts for approximately 0.7% of Oak Ridge Investments LLC's portfolio, making the stock its 28th largest holding. Oak Ridge Investments LLC's holdings in Intuitive Surgical were worth $9,012,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ISRG. Chilton Capital Management LLC raised its stake in Intuitive Surgical by 614.3% in the 1st quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 43 shares during the period. Parvin Asset Management LLC bought a new stake in Intuitive Surgical in the 4th quarter valued at about $26,000. Global Financial Private Client LLC raised its stake in Intuitive Surgical by 253.3% in the 1st quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock valued at $26,000 after acquiring an additional 38 shares during the period. Elite Financial Inc. bought a new stake in shares of Intuitive Surgical during the first quarter valued at about $26,000. Finally, LFA Lugano Financial Advisors SA bought a new stake in shares of Intuitive Surgical during the first quarter valued at about $30,000. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Stock Performance

ISRG traded up $3.18 during midday trading on Friday, hitting $480.26. The stock had a trading volume of 1,436,064 shares, compared to its average volume of 2,192,612. The company has a market cap of $172.16 billion, a P/E ratio of 66.98, a price-to-earnings-growth ratio of 5.03 and a beta of 1.59. The business has a fifty day moving average of $508.75 and a 200 day moving average of $525.16. Intuitive Surgical, Inc. has a 1 year low of $425.00 and a 1 year high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.93 by $0.26. The business had revenue of $2.44 billion during the quarter, compared to analyst estimates of $2.35 billion. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%. Intuitive Surgical's revenue for the quarter was up 21.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.78 earnings per share. On average, equities research analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Piper Sandler reiterated an "overweight" rating and set a $595.00 price target (up from $575.00) on shares of Intuitive Surgical in a research report on Wednesday, July 23rd. Evercore ISI upped their price target on Intuitive Surgical from $470.00 to $550.00 and gave the company an "in-line" rating in a research report on Tuesday, July 8th. Wells Fargo & Company upped their price target on Intuitive Surgical from $559.00 to $599.00 and gave the company an "overweight" rating in a research report on Wednesday, July 23rd. UBS Group upped their price target on Intuitive Surgical from $547.00 to $585.00 and gave the company a "neutral" rating in a research report on Wednesday, July 23rd. Finally, Robert W. Baird decreased their price target on Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 23rd. One analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $595.95.

Insiders Place Their Bets

In other news, EVP Myriam Curet sold 4,500 shares of the firm's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $492.48, for a total value of $2,216,160.00. Following the transaction, the executive vice president owned 353 shares in the company, valued at approximately $173,845.44. This trade represents a 92.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Mark Brosius sold 216 shares of the firm's stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $563.11, for a total transaction of $121,631.76. Following the completion of the transaction, the senior vice president owned 907 shares in the company, valued at $510,740.77. This represents a 19.23% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 15,839 shares of company stock valued at $7,896,972 over the last quarter. 0.70% of the stock is owned by corporate insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.